Back to Journals » ImmunoTargets and Therapy » Call For Papers

ImmunoTargets and Therapy

ISSN: 2253-1556

The following Article Collections/ Thematic Series are currently open for submissions:

Modern diagnosis of autoimmune diseases

Dove Medical Press is pleased to invite you to submit your work to an upcoming Thematic Series on “Modern diagnosis of autoimmune diseases” in Immunotargets and Therapy.

When submitting your work, please use the promo code URAJX for 20% off the advertised article processing charge and to indicate that your manuscript should be considered for the Thematic Series on “Modern diagnosis of autoimmune diseases”. For any enquiries, please email Rebecca Kearns, Commissioning Editor, at [email protected].

The deadline for submission of manuscripts is September 30th, 2023.

About the Thematic Series

There are more than 80 known types of autoimmune disease, and due to their heterogeneity and often unknown cause, diagnosis of specific disorders can be complex and often requires multiple investigations. These diseases are often chronic and can be debilitating in nature, which can lead to a reduced quality of life. As well as affecting patients on a physical, physiological, psychological, and financial level, it also affects their families and communities. Fast and efficient diagnosis of these diseases is crucial in finding efficacious therapeutic options. In this thematic series we will publish studies and reviews that focus on topics surrounding the diagnosis of autoimmune disorders.

The journal Editors are seeking original research and review article submissions within the theme of “Modern diagnosis of autoimmune diseases”. Papers addressing the following issues are welcomed:

• Diagnosis of rare autoimmune disorders
• Novel biomarkers in autoimmune disease
• Genetic and molecular diagnosis of autoimmune disease
• Challenges of differential diagnosis in autoimmune disease
• Diagnosis of Multiple Autoimmune Syndrome (MAS)
• Machine learning and diagnostic technologies in autoimmune disease
• Obstacles and barriers to early and accurate diagnosis
• Multidisciplinary approaches to autoimmune disease diagnosis
• Insights into modern diagnosis of specific autoimmune diseases

Submit your manuscript

View all papers in this thematic series

Oral Vaccines for Infectious and or Non-Infectious Diseases

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Oral Vaccines for Infectious and or Non-Infectious Diseases" in ImmunoTargets and Therapy.

Vaccines are biological formulations of antigenic material(s) and excipients capable of inducing protection against one or more infectious or malignant diseases of interest. Next to safe drinking water, vaccines have remained the cornerstone of public health interest as they remain the most cost-effective way to prevent infectious and malignant diseases. Vaccines are most commonly administered by needle injections and only a few are administered through the oral or the nasal routes. Oral vaccines are more advantageous than injection-based vaccines for a number of reasons: including increased safety, ease of administration and compliance, and simpler manufacture and delivery. Additionally, the oral route allows for the development of cellular and humoral immune responses at mucosal and systemic locations to provide a more extensive and long-lasting immunity. Convenient for all ages, oral vaccines can offer immunity against varieties of infectious diseases. 

Edible vaccines, also referred to as food vaccines, plant-based vaccines, or green vaccines, are a group of newly emerging oral vaccines and may later become possible alternatives to cold-chain vaccines, especially for developing countries. The concept of using edible tissues of genetically engineered crops as a manufacturing and delivery system for biologics was first introduced in the early 1990s by Dr. Charles Arntzen and his associates. This plant-based vaccine can be developed against both communicable and non-communicable diseases and can be taken either by eating the edible part of the transgenic crop or by oral administration of the refined protein extract. 

It is essential to invest more research efforts into developing stable oral vaccines as a delivery route. Furthermore, oral vaccines which are grown in antigen-producing plants will eliminate the need for transportation and cold chains, and will overcome the challenges of inaccessibility to vaccines in many rural communities of developing countries. More scientific studies are needed in various aspects of oral vaccine to tackle myriads of human and veterinary diseases. 

We welcome papers covering In silico studies relating to any aspects of epitope identification and oral vaccine design: Immunology and immunological aspects of oral vaccines; Animal models of diseases (communicable and non-communicable) being experimented upon with any form of oral vaccine; Oral and edible vaccines; Implementation Science and management; Oral vaccines for animal and human diseases; and other aspects of oral vaccines. Original research, Commentaries, Letters to the Editor, and Reviews are welcome.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. 

Please submit your manuscript on our website, quoting the promo code XYTAJ to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 1 July 2024.

Guest Advisors

Angus Nnamdi Oli, Nnamdi Azikiwe University

[email protected]

Dr. Oli, a trained Pharmacist, is a Reader at Nnamdi Azikiwe University, Awka, Nigeria with expertise in Vaccinology, Immunology, Pharmaceutical Microbiology Quality Assurance and Infectious Disease Researches. He is listed among the first 500 scholars in Nigeria by Scopus for the years 2022 and 2023. He has undergone several trainings including Massive Open Online Courses (MOOC) on Implementation Research (IR) with a focus on Infectious Diseases of Poverty (IDP) organised by African Regional Training Centre, University of Ghana School of Public Health and the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR).

Adekunle Rowaiye, National Biotechnology Development Agency

[email protected]

Dr. Rowaiye is a Veterinarian and Pharmaceutical Biotechnologist. His research interest is in the discovery, design, and evaluation of drug candidates which include small molecules, natural products, peptides, and proteins. Dr Rowaiye has several publications in international journals and he is presently working on the discovery of drug candidates that will retard the aging process and prevent neurodegenerative diseases.

View all papers in this article collection

Call For Papers

To see where ImmunoTargets and Therapy is indexed online view the Journal Metrics.

What is the advantage to you of publishing in ImmunoTargets and Therapy?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. ImmunoTargets and Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
ImmunoTargets and Therapy is indexed on PubMed Central (title abbreviation: Immunotargets Ther). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Michael R Shurin
ImmunoTargets and Therapy

Email: Editor-in-Chief